LA
ANIK icon

Lucus Advisors’s Anika Therapeutics ANIK Stock Holding History

Lucus Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-6,343
Closed -$284K – 254
2016
Q1 		$284K Sell
6,343
-6,837
-52% -$277K 0.17% 246
2015
Q4 		$503K Buy
13,180
+406
+3% +$15.5K 0.31% 30
2015
Q3 		$407K Sell
12,774
-2,550
-17% -$88.9K 0.23% 258
2015
Q2 		$506K Buy
15,324
+1,803
+13% +$64.3K 0.24% 108
2015
Q1 		$557K Buy
13,521
+1,848
+16% +$74.7K 0.28% 37
2014
Q4 		$476K Buy
+11,673
New +$456K 0.21% 126

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Lucus Advisors's ANIK Position: Q2 2016 in Review

Lucus Advisors sold out of Anika Therapeutics (ANIK) in Q2 2016, closing a stake of 6,343 shares — an estimated $284K sold.

Lucus Advisors first reported a position in ANIK in Q4 2014 and held it in 6 quarters. The position peaked at $557K in Q1 2015. 160 funds tracked by Wall St. Rank hold ANIK as of Q2 2016.

  • Lucus Advisors reported no remaining Anika Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Lucus Advisors sold 6,343 Anika Therapeutics shares in Q2 2016, an estimated $284K.
  • Lucus Advisors first reported a position in Anika Therapeutics in Q4 2014 and held it in 6 quarters.
  • Lucus Advisors's Anika Therapeutics position peaked at $557K in Q1 2015.
  • 160 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2016.

Based on Lucus Advisors's 13F filing for Q2 2016, filed 27 Jul 2016.